Evolving use of liquid biopsy in non-small-cell-lung cancer patients

Research output: Contribution to journalArticlepeer-review


Liquid biopsy is routinely used to detect epidermal growth factor receptor mutations in advanced or metastatic lung cancer, due to some limitations of tissue genotyping, especially at relapse. However, the existence of a non-marginal proportion of oncogene-addicted lung cancers that can benefit from target therapy is rapidly expanding clinical relevance of plasma genotyping. Apart from static assessment of mutations in circulating free DNA, the fact that liquid biopsy is minimally invasive and can be repeated several times makes it a suitable assay for the dynamic monitoring of cancer response to treatment. It is likely that quantitative mutation assessment by liquid biopsy will be increasingly included in the design of innovative clinical trials for patient stratification purposes.

Original languageEnglish
Pages (from-to)23-25
Number of pages3
JournalInternational Journal of Biological Markers
Issue number1_suppl
Publication statusPublished - Feb 2020


  • Diagnostics and Pharmacogenomics
  • Disease sites
  • EGF and/or receptors
  • Lung Cancer
  • Markers
  • Methods
  • Molecular

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Clinical Biochemistry
  • Cancer Research


Dive into the research topics of 'Evolving use of liquid biopsy in non-small-cell-lung cancer patients'. Together they form a unique fingerprint.

Cite this